Thank you for all your support thus far, 2019 started with a bang for Esco Ventures and we are excited to be making a few announcements here.
We welcome your feedback and comments.
With Best Regards,
The Esco Ventures Team
July 2, 2019 | News and Updates
Esco Ventures Vision
Esco Ventures is the life sciences investment arm of Esco Group dedicated to nurturing promising early-stage start-ups with novel innovations and technologies in the life sciences arena that will improve human well-being and quality of life.
Entrepreneurial Scientists as Catalysts
for a Growing Biotech Ecosystem
In March 2019, Esco Ventures had the pleasure of having Prof. Harvey Lodish, Prof. Dario Campana, Prof. Antonio Bertoletti, Dr. Danny Soon and our CEO, XQ Lin come together to share about various topics relating to biotech development, where many of us learnt so much from the sharing of their experiences.
Maiden Therapeutics was incorporated in June 2019. Dr. Damien Keogh, the CEO & Co-Founder of Maiden, has been incubating this company at ESCO Ventures X for over a year. Maiden has developed an interdisciplinary drug discovery approach, through the Human Microbiome MedicinesTM (HMMTM) discovery platform, to tap the human milk microbiome and identify microbiome-derived small molecules and peptides targeting human diseases. In addition to the support of ESCO Ventures, Maiden has and a strong team of advisors, scientists, and clinical collaborators.
The Scientific Advisory Board
Prof. Kim Lewis
Dr. Terence A. Kelly
To find out more about Maiden Therapeutics, please visit:
Esco Ventures Advisory Board
Esco Ventures, the corporate venture arm of Esco Group, and also a leading Asia based global biotech venture builder via its Esco Ventures X arm, is proud to announce the expansion of its global advisory board.
Prof. Harvey Lodish
Dr. Bertil Lindmark
Updates from our Investee Companies
Carmentix is proud to announce that we have presented our initial clinical results at the Society for Maternal-Fetal Medicine's 39th Annual Pregnancy meeting from the 11th to 16th February 2019 in Las Vegas.
Using our proprietary panel of biomarkers, we have successfully completed the initial phase of our discovery and validation cohort study in a multicenter clinical study at two sites in Melbourne. It was indeed a positive experience to share our results with an esteemed panel of clinicians and researchers.
"We are excited about exposing our results for the first time. After 3 years of development, we have achieved excellent clinical results with a high sensitivity and specificity for preterm birth prediction in both the retrospective and prospective clinical studies. As the feedbacks received during the conference from clinicians were extremely positive, it seems like there will be great anticipation for further results to be released later this year." said CEO of Carmentix, Dr. Nir Arbel.
Details of the abstract can be viewed at here.
Esco Ventures Pte Ltd
LaunchPad @ one-north
71 Ayer Rajah Crescent